drugset
drugset / Trial / NCT05380635

PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma

NCT05380635 ↗

Phase 2 Completed 9 enrolled Soligenix
NaSingle-groupOpen-labelOther

Summary

To assess the blood levels of hypericin and any electrocardiogram (ECG) changes during 8 weeks of HyBryte (topical hypericin ointment) photodynamic therapy.

Timeline

Start
2022-05-09
Primary completion
2022-08-16
Completion
2022-08-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Hypericin Other / unclassified 0.25 % Topical

Indications

mycosis fungoides